User login
Key clinical point: Erenumab led to decreased migraine frequency in patients with migraine with a history of aura.
Main finding: Compared with placebo, the change in monthly migraine days at week 12 was greater with 70 mg and 140 mg of erenumab in patients with episodic (least-squares mean differences [LSM] −1.1; 95% CI –1.7 to –0.6 and −0.9; 95% CI –1.6 to –0.2; respectively) and chronic (LSM −2.1; 95% CI –3.8 to –0.5 and −3.1; 95% CI –4.8 to –1.4, respectively) migraine with aura.
Study details: This was a post hoc subgroup analysis of 4 double-blind randomized clinical trials involving 2,443 adults with chronic or episodic migraine who received either erenumab (70 or 140 mg; n = 1,400) or placebo (n = 1,043).
Disclosures: Amgen Inc. sponsored the study. M Ashina reported being a principal investigator for ongoing trials for various sources including Amgen and, along with some co-authors, receiving speaking/teaching honoraria, advisory/consultation fees, or research grants from; or being a board member of, various companies. A few authors served as employees and stockholders of Amgen during the study period. Amgen and Novartis have co-developed erenumab.
Source: Ashina M et al. JAMA Neurol. 2021 (Dec 20). Doi: 10.1001/jamaneurol.2021.4678.
Key clinical point: Erenumab led to decreased migraine frequency in patients with migraine with a history of aura.
Main finding: Compared with placebo, the change in monthly migraine days at week 12 was greater with 70 mg and 140 mg of erenumab in patients with episodic (least-squares mean differences [LSM] −1.1; 95% CI –1.7 to –0.6 and −0.9; 95% CI –1.6 to –0.2; respectively) and chronic (LSM −2.1; 95% CI –3.8 to –0.5 and −3.1; 95% CI –4.8 to –1.4, respectively) migraine with aura.
Study details: This was a post hoc subgroup analysis of 4 double-blind randomized clinical trials involving 2,443 adults with chronic or episodic migraine who received either erenumab (70 or 140 mg; n = 1,400) or placebo (n = 1,043).
Disclosures: Amgen Inc. sponsored the study. M Ashina reported being a principal investigator for ongoing trials for various sources including Amgen and, along with some co-authors, receiving speaking/teaching honoraria, advisory/consultation fees, or research grants from; or being a board member of, various companies. A few authors served as employees and stockholders of Amgen during the study period. Amgen and Novartis have co-developed erenumab.
Source: Ashina M et al. JAMA Neurol. 2021 (Dec 20). Doi: 10.1001/jamaneurol.2021.4678.
Key clinical point: Erenumab led to decreased migraine frequency in patients with migraine with a history of aura.
Main finding: Compared with placebo, the change in monthly migraine days at week 12 was greater with 70 mg and 140 mg of erenumab in patients with episodic (least-squares mean differences [LSM] −1.1; 95% CI –1.7 to –0.6 and −0.9; 95% CI –1.6 to –0.2; respectively) and chronic (LSM −2.1; 95% CI –3.8 to –0.5 and −3.1; 95% CI –4.8 to –1.4, respectively) migraine with aura.
Study details: This was a post hoc subgroup analysis of 4 double-blind randomized clinical trials involving 2,443 adults with chronic or episodic migraine who received either erenumab (70 or 140 mg; n = 1,400) or placebo (n = 1,043).
Disclosures: Amgen Inc. sponsored the study. M Ashina reported being a principal investigator for ongoing trials for various sources including Amgen and, along with some co-authors, receiving speaking/teaching honoraria, advisory/consultation fees, or research grants from; or being a board member of, various companies. A few authors served as employees and stockholders of Amgen during the study period. Amgen and Novartis have co-developed erenumab.
Source: Ashina M et al. JAMA Neurol. 2021 (Dec 20). Doi: 10.1001/jamaneurol.2021.4678.